当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
DENGVAXIA, Dengue Tetravalent Vaccine, Live
药品名称
DENGVAXIA, Dengue Tetravalent Vaccine, Live
承诺描述
Deferred study CPIF 133 to evaluate safety and effectiveness of DENGVAXIA in infants and children 6 months to less than 2 years of age.
承诺状态描述
The study has not been initiated, but does not meet criterion for delayed.